Clinical Trial Update: Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial update showing results for Vorinostat and Bortezomib in advanced soft tissue sarcoma; the study is completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2013-11-21